Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors
<p>IRVINE, Calif., Sept. 24, 2026 /PRNewswire/ -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage...</p>
Read original article ↗
Related Articles
Inaugural New York showcase brought together emerging fashion, Vanderbilt heritage and immersive technology at Vanderbil
PLACE acquires fintech Maxwell, bolsters its platform for lenders and institutional partners
Maxwell, a leading provider of AI-powered mortgage technology and services, touched nearly 1 in 10 mortgage transactions
Ringg’s AI agents resolve up to 65% of customer calls with OpenAI
Using GPT-5.6, Ringg powers multilingual agents across voice, chat, WhatsApp, and web for 90% less cost vs. GPT-4.1.
SwitchBot Launches Robot Vacuum K11+ Pro with an Ultra-Compact Auto-Empty Design
TOKYO, Sept. 24, 2026 /PRNewswire/ -- SwitchBot, a leading provider of AI-enabled embodied home robotics systems, today